Premium
FDA jeopardizes the lives of lung transplant recipients and in the process severely increases the cost to develop new immunosuppression
Author(s) -
Klintmalm Goran B.,
Kaplan Bruce,
Kirk Allan D.
Publication year - 2019
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.15215
Subject(s) - medicine , azathioprine , immunosuppression , intensive care medicine , lung transplantation , organ transplantation , clinical trial , transplantation , disease
The authors express concern that recent FDA rules will make common immunosuppressive protocols unavailable to Medicare lung transplant recipients.